Drug-Tolerant, Chemiluminescent Lateral Flow Immunoassay Platform for the Determination of Neutralizing Anti-Drug Antibodies.

ABSTRACT: Administration of mAb therapeutics often elicits the production of neutralizing anti-drug antibodies (nADA) in patients. Current nADA assays are drug-sensitive and detect only free nADA, thereby overlooking drug-bound antibodies and reducing sensitivity. An extra preparatory step of acid dissociation is often applied to resolve the immunocomplexes and subsequently detect the resultant free nADA separately. This tedious sample preparation limits them to lab settings and exposes the antibodies to harsh conditions. Here, a modified lateral flow assay platform, namely sequential binding flow immunoassay (SBFIA) is presented for nADA determination that circumvents the drug's interference through a distinctive approach. Drawing inspiration from chromatography, sequential binding events (competit

SUBMITTER: Kokojka F 

PROVIDER: S-EPMC12508725 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature